Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO-203-2C + Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT02658396Phase 1Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GO-203-2C in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 21 days. Status: withdrawn.
02
Drugs
GO-203-2C
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02658396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658396.